Published in
Wiley, British Journal of Clinical Pharmacology, 9(86), p. 1703-1710, 2020
DOI: 10.1111/bcp.14337
Links
Tools
Cost‐effectiveness and financial risks associated with immune checkpoint inhibitor therapy
This paper was not found in any repository, but could be made available legally by the author.
Full text: Unavailable
Published version:
archiving forbidden
Data provided by 